Abstract
1 page.-- Poster presentation.-- This article is part of the supplement: AIDS Vaccine 2009.
Highlights
The attenuated poxvirus vectors MVA and NYVAC are in clinical trials against HIV/AIDS
AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
We have analyzed the ability of a soluble form of hexameric CD40L to stimulate specific immune responses to HIV antigens when inoculated in mice during priming with DNA and in the booster with MVA or NYVAC, expressing the vectors HIV-1 Env, Gag, Pol and Nef antigens from clade B
Summary
The attenuated poxvirus vectors MVA and NYVAC are in clinical trials against HIV/AIDS. Multimeric soluble CD40 ligand efficiently enhances HIV
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
